Twelve-Month Treatment of Overactive Bladder

Publisher Website
Google Scholar
Abstract
Context: Tolterodine is a bladder-selective antimuscarinic agent designed for the treatment of overactive bladder. Traditional antimuscarinic therapies are poorly tolerated due to a high incidence of anticholinergic adverse events and consequently few patients remain on long term therapy. Objective: To evaluate the long term efficacy and tolerability of tolterodine in patients with symptoms of overactive bladder. Design: Twelve-month open-label extension of 4 randomised, placebo-controlled, double-blind, multinational, multicentre trials of 4 weeks’ duration. Patients: 714 patients (aged 18 to 92 years) with symptoms of overactive bladder who completed the double-blind portion of the studies. Intervention: Tolterodine 2mg twice daily for up to 12 months. Main outcome measures: Micturition diary variables: number of micturitions per 24 hours, number of urge incontinence episodes per 24 hours, mean urine volume voided per micturition. Safety variables: adverse events, study discontinuation rate. Results: A total of 441 patients (62%) completed 12 months’ open-label treatment with tolterodine, which significantly reduced the number of micturitions per 24 hours [mean change −2.4, 95% confidence interval (CI) −2.7 to −2.2, median change −20%, p < 0.0001] and number of urge incontinence episodes per 24 hours (mean change −1.3, 95% CI −1.6 to −1.0, median change −74%, p < 0.0001), while the mean volume voided per micturition was significantly increased (+33ml, 95% CI +28 to +38, median change +18%; p < 0.0001). 41% of patients reported dry mouth (27% mild, 10% moderate, 3% severe). Dosage reduction to 1mg twice daily was required in 23% of patients. 15% of patients withdrew from the study due to adverse events, with 5% having associated dry mouth. Conclusions: The high percentage of patients completing 12 months’ treatment indicates that tolterodine is an effective and well tolerated agent for long term treatment of overactive bladder.